Davis JA - Search Results

1

Organ toxicities associated with chimeric antigen receptor T-cell therapy.

McGann M, Gaffney KJ, Davis JA, Smith D, Hashmi H. McGann M, et al. Among authors: davis ja. Leuk Lymphoma. 2023 Feb;64(2):491-494. doi: 10.1080/10428194.2022.2148213. Epub 2022 Nov 23. Leuk Lymphoma. 2023. PMID: 36416619 No abstract available.

2

The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.

Davis JA, Shockley A, Hashmi H. Davis JA, et al. J Oncol Pharm Pract. 2022 Jun;28(4):960-968. doi: 10.1177/10781552211073517. Epub 2022 Jan 10. J Oncol Pharm Pract. 2022. PMID: 35006032 Review.

3

'Save the day with a Stem Cell Rescue': Use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy.

Hashmi H, Shockley A, Davis JA. Hashmi H, et al. Among authors: davis ja. Bone Marrow Transplant. 2022 Mar;57(3):504-506. doi: 10.1038/s41409-022-01570-4. Epub 2022 Jan 17. Bone Marrow Transplant. 2022. PMID: 35039623 No abstract available.

4

ANDROMEDA: Dara-VCd for newly diagnosed AL amyloidosis: the next galaxy or a new standard of care?

Davis JA, Hashmi H. Davis JA, et al. Expert Opin Biol Ther. 2022 Apr;22(4):445-447. doi: 10.1080/14712598.2022.2035357. Epub 2022 Feb 2. Expert Opin Biol Ther. 2022. PMID: 35084284 No abstract available.

5

Incidence of Pneumocystis jirovecii pneumonia (PJP) in patients receiving BTK inhibitors who did not receive PJP prophylaxis.

Davis JA, Graham A, Hendrickson L, Hess B, Gaffney K. Davis JA, et al. Leuk Lymphoma. 2022 Aug;63(8):2016-2018. doi: 10.1080/10428194.2022.2056179. Epub 2022 Mar 27. Leuk Lymphoma. 2022. PMID: 35341452 No abstract available.

6

Efficacy and safety of allogeneic hematopoietic stem cell transplant in adults with hemophagocytic lymphohistiocytosis: a systematic review of literature.

Masood A, Wahab A, Iqbal Q, Davis J, Ehsan H, Hashmi H. Masood A, et al. Bone Marrow Transplant. 2022 Jun;57(6):866-873. doi: 10.1038/s41409-022-01668-9. Epub 2022 Apr 11. Bone Marrow Transplant. 2022. PMID: 35411107 Review.

7

'Fast but not so Furious': Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy.

Davis JA, Youngberg H, Gaffney K, Duco M, Hashmi H. Davis JA, et al. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e680-e684. doi: 10.1016/j.clml.2022.03.006. Epub 2022 Mar 22. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35414476

8

Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma.

Davis J, McGann M, Shockley A, Hashmi H. Davis J, et al. Expert Rev Hematol. 2022 Jun;15(6):473-475. doi: 10.1080/17474086.2022.2081147. Epub 2022 May 26. Expert Rev Hematol. 2022. PMID: 35603733 No abstract available.

9

Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Davis JA, Rizzieri DA, Lane AA, Taylor J, Faisal MS, Vasu S, Soong D, Li H, Herbst A, Greenwell IB. Davis JA, et al. Leuk Lymphoma. 2022 Nov;63(11):2757-2759. doi: 10.1080/10428194.2022.2090552. Epub 2022 Jun 21. Leuk Lymphoma. 2022. PMID: 35727174 No abstract available.

10

Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy.

McGann M, Davis JA, Gaffney KJ, Smith D, Edwards K, Hess BT, Hashmi H. McGann M, et al. Among authors: davis ja. Transplant Cell Ther. 2022 Sep;28(9):583-585. doi: 10.1016/j.jtct.2022.06.021. Epub 2022 Jun 30. Transplant Cell Ther. 2022. PMID: 35781100 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,056 results

Search Page

Filters